Alpha DNA Investment Management LLC Trims Stake in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)

Alpha DNA Investment Management LLC lessened its position in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNSFree Report) by 35.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 49,664 shares of the biopharmaceutical company’s stock after selling 27,419 shares during the quarter. Alpha DNA Investment Management LLC owned approximately 0.09% of Marinus Pharmaceuticals worth $540,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in MRNS. China Universal Asset Management Co. Ltd. boosted its stake in shares of Marinus Pharmaceuticals by 383.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,307 shares of the biopharmaceutical company’s stock valued at $69,000 after buying an additional 5,003 shares during the period. SG Americas Securities LLC acquired a new position in Marinus Pharmaceuticals during the 4th quarter worth approximately $134,000. Sherbrooke Park Advisers LLC purchased a new stake in shares of Marinus Pharmaceuticals in the 3rd quarter valued at approximately $141,000. Acuta Capital Partners LLC acquired a new stake in shares of Marinus Pharmaceuticals in the 3rd quarter valued at $157,000. Finally, Trexquant Investment LP purchased a new stake in shares of Marinus Pharmaceuticals during the 4th quarter worth $553,000. Institutional investors and hedge funds own 98.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on MRNS. Oppenheimer reaffirmed a “market perform” rating and issued a $9.00 target price on shares of Marinus Pharmaceuticals in a report on Thursday, March 7th. Truist Financial reduced their target price on shares of Marinus Pharmaceuticals from $25.00 to $10.00 and set a “buy” rating for the company in a report on Wednesday, April 17th. StockNews.com lowered Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, March 6th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $3.00 price objective (down from $24.00) on shares of Marinus Pharmaceuticals in a research note on Monday, April 15th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $28.00 target price on shares of Marinus Pharmaceuticals in a research note on Wednesday, April 10th. One analyst has rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, Marinus Pharmaceuticals presently has an average rating of “Hold” and an average price target of $13.79.

Check Out Our Latest Research Report on Marinus Pharmaceuticals

Marinus Pharmaceuticals Price Performance

Marinus Pharmaceuticals stock traded down $0.04 during midday trading on Friday, reaching $1.42. 866,191 shares of the company were exchanged, compared to its average volume of 1,336,947. Marinus Pharmaceuticals, Inc. has a 1 year low of $1.11 and a 1 year high of $11.26. The company has a market capitalization of $78.00 million, a price-to-earnings ratio of -0.54 and a beta of 1.14. The firm’s 50-day simple moving average is $3.53 and its 200-day simple moving average is $7.22. The company has a debt-to-equity ratio of 5.68, a quick ratio of 2.93 and a current ratio of 3.07.

Marinus Pharmaceuticals (NASDAQ:MRNSGet Free Report) last announced its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, hitting the consensus estimate of ($0.68). The business had revenue of $7.68 million for the quarter, compared to analyst estimates of $8.61 million. Marinus Pharmaceuticals had a negative net margin of 513.80% and a negative return on equity of 518.13%. On average, analysts anticipate that Marinus Pharmaceuticals, Inc. will post -1.87 EPS for the current year.

Marinus Pharmaceuticals Profile

(Free Report)

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.

Read More

Want to see what other hedge funds are holding MRNS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Marinus Pharmaceuticals, Inc. (NASDAQ:MRNSFree Report).

Institutional Ownership by Quarter for Marinus Pharmaceuticals (NASDAQ:MRNS)

Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.